—
CD ComputaBio, a reliable computational biology service provider in New York, is committed to assisting research and trials, as well as providing access to the latest software, technologies, and expertise at competitive prices and with fast turnarounds for researchers. Recently, CD ComputaBio introduced the BIOVIA Discovery Studio software, providing comprehensive modeling and simulation capabilities for computational chemists, computational biologists, and scientists engaged in small or large molecular life science research and development.
The Discovery Studio (abbreviated as DS) software, based on the Windows/Linux system and personal computer, is a novel computational design for molecular modeling and simulation in the life sciences field. It is applied in the study of protein structures and functions, as well as drug discovery, providing scientists with easy-to-use tools for the advancement of protein simulation, optimization, and potential drug design. Through high-quality graphics, proven technologies, and an integrated environment, DS has incorporated the storage and management of experimental data with professional-level modeling and simulation tools, providing a platform for team information sharing and enhancing research cooperation.
Currently, the major functions of the DS platform cover protein characterization, homology modeling, molecular mechanics calculations, molecular dynamics simulations, structure-based drug design tools (including ligand-protein interaction, new drug design, and molecular docking), small molecule-based drug design tools (quantitative structure-activity relationship, pharmacophore, database screening, ADMET), the design and analysis of combinatorial libraries, etc. In addition, the DS software can also be applied to the following research fields for life science development: new drug discovery, bioinformatics, structural biology, enzymology, immunology, virology, genetics and developmental biology, tumor research, etc.
Utilizing this DS software platform, CD ComputaBio can provide customers with a full range of biopharmaceutical design support, including but not limited to hybrid QM/MM calculation, pharmacophore modeling, and polymer design and validation.
One of the major bottlenecks encountered in the development of biotherapeutics regards the instability of biopharmaceuticals, such as protein aggregation, especially during long-term storage. Given this, the discovery of spatial aggregation propensity codes utilizing the DS software can help scientists rank antibodies and other proteins according to their respective aggregation propensities, thus, determining sites that govern the revealed phenomenon. This is suggested for the early drug discovery stage all the way through drug development, ensuring the selection and engineering of stable biomolecules and drug candidates.
“Discovery Studio makes it easy to characterize large and small molecules, investigate systems, identify leads, and optimize candidate molecules. In addition, it is built on the BIOVIA platform and adapted to the pipeline navigation technology, allowing scientists to quickly automate and complete routine tasks, integrate third-party applications, and even deploy models,” stated the Chief Scientist of CD ComputaBio.
About CD ComputaBio
With years of experience, CD ComputaBio has become a professional computational biology service provider. The company can support customers with comprehensive computational biology analytical services covering molecular dynamics simulation, drug design, virtual screening, quantum chemical calculations, etc., utilizing its extensive experience and powerful technology in computational science.
Contact Info:
Name: Vivian Smith
Email: Send Email
Organization: CD ComputaBio
Website: https://www.computabio.com/
Release ID: 89088542
Google
RSS